Mylan NV (MYL)

21.69
NASDAQ : Health Technology
Prev Close 22.24
Day Low/High 21.66 / 22.90
52 Wk Low/High 16.63 / 39.59
Avg Volume 7.24M
Exchange NASDAQ
Shares Outstanding 515.87M
Market Cap 11.47B
EPS 0.70
P/E Ratio 302.71
Div & Yield N.A. (N.A)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BLX, CRMD, DHX, FTAI, HCP, MHO, MRC, XPO Downgrades: AINC, ARW, BPY, CRAY, EARN, FLR, HRTG, IDSY, MYL, PATK, PXLW, TRQ, TWI, WMS Initiations: BCDA, USX Read on to get TheStreet Quant Ratings' detailed report:

SHAREHOLDER ALERT: WeissLaw LLP Investigates Mylan N.V.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Mylan N.V.

NEW YORK, July 29, 2019 /PRNewswire/ --  WeissLaw LLP  is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Mylan N.

While No Magic Pill, Mylan Deal Might Just Revive Drugmaker

While No Magic Pill, Mylan Deal Might Just Revive Drugmaker

The merger with Pfizer's off-patent branded medicines business may be a life-preserver for bulls and provide meaningful expansion across geographical regions while leveraging Pfizer's commercialization capabilities.

Trading Pfizer Shares on Earnings, Tie-Up With Mylan

Trading Pfizer Shares on Earnings, Tie-Up With Mylan

Pfizer reports earnings and announces a massive tie-up with Mylan, sending shares of the latter shooting higher.

Two Pharmaceutical Stocks That Jim Cramer's Watching

Two Pharmaceutical Stocks That Jim Cramer's Watching

Jim Cramer's eyeing Merck and Pfizer. Here's why.

A Look at Mylan's New Post-Merger Management

A Look at Mylan's New Post-Merger Management

What new management means for Mylan shareholders moving forward.

Pfizer to Combine Off-Patent Drug Division With Mylan

Pfizer to Combine Off-Patent Drug Division With Mylan

Mylan and Pfizer agreed to combine their off-patent drug businesses in an all-stock deal that will create a new company based in the United States.

Grab Yourself a Cold Brew - Jim Cramer on Starbucks, Earnings and Mylan

Grab Yourself a Cold Brew - Jim Cramer on Starbucks, Earnings and Mylan

Jim Cramer tackles Starbucks, the Federal Reserve, earnings and Mylan ahead of a week filled with potentially market-moving headlines.

Mylan Will Bounce Today and Become Stronger on the Short-Term Charts

Mylan Will Bounce Today and Become Stronger on the Short-Term Charts

Pfizer is in talks to merge its off-patent drug operation with Mylan.

Mylan Jumps on Deal With Pfizer to Form New Company

Mylan Jumps on Deal With Pfizer to Form New Company

Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.

Beyond Meat, Pfizer, Mylan, Amazon, Federal Reserve - 5 Things You Must Know

Beyond Meat, Pfizer, Mylan, Amazon, Federal Reserve - 5 Things You Must Know

U.S. stock futures are mixed as Wall Street prepares for a likely quarter-point rate cut from the Federal Reserve; Beyond Meat reports earnings on Monday; Pfizer will combine its off-patent drugs business with Mylan; Exact Sciences reportedly is in negotiations to buy Genomic Health.

Statement From Mylan's Board Of Directors Regarding Retirement Of CEO And Board Member Heather Bresch In Conjunction With The Combination Of Mylan And Upjohn, A Division Of Pfizer

Statement From Mylan's Board Of Directors Regarding Retirement Of CEO And Board Member Heather Bresch In Conjunction With The Combination Of Mylan And Upjohn, A Division Of Pfizer

HERTFORDSHIRE, England and PITTSBURGH, July 29, 2019 /PRNewswire/ -- Mylan's Board of Directors today shared the following statement regarding Heather Bresch's retirement, which will be effective upon the closing of the combination of Mylan and Upjohn, a...

Mylan And Upjohn, A Division Of Pfizer, To Combine, Creating A New Champion For Global Health Uniquely Positioned To Fulfill The World's Need For Medicine

Mylan And Upjohn, A Division Of Pfizer, To Combine, Creating A New Champion For Global Health Uniquely Positioned To Fulfill The World's Need For Medicine

- Delivers enhanced global scale and geographic reach, including leading positions in China and other emerging markets

Mylan Shares Surge Amid Reports of Off-Patent Drug Combination with Pfizer

Mylan Shares Surge Amid Reports of Off-Patent Drug Combination with Pfizer

Mylan shares were indicated sharply higher Monday amid reports the generic drugs group is set to create a separate business with Pfizer for off-patent pharmaceuticals.

Mylan Reports Second Quarter 2019 Results

Mylan Reports Second Quarter 2019 Results

HERTFORDSHIRE, England and PITTSBURGH, July 29, 2019 /PRNewswire/ --  Mylan N.V.

Pfizer, Mylan Plan to Combine Generic Drug Business: Reports

Pfizer, Mylan Plan to Combine Generic Drug Business: Reports

Shareholders of Mylan would get around 40% of the newly formed business and Pfizer shareholders would get the remaining 60%, according to Reuters.

Mylan Falls on Report That EpiPen Shortage Is Hurting Patients and Pharmacists

Mylan Falls on Report That EpiPen Shortage Is Hurting Patients and Pharmacists

Novartis said earlier this week it would make a generic EpiPen to fill the void of Mylan's shortage.

Mylan And Atomo Diagnostics Announce WHO Prequalification Approval For Mylan HIV Self Test

Mylan And Atomo Diagnostics Announce WHO Prequalification Approval For Mylan HIV Self Test

HERTFORDSHIRE, England and PITTSBURGH and SYDNEY, July 8, 2019 /PRNewswire/ -- Global pharmaceutical company  Mylan N.

Theravance Biopharma And Mylan Expand YUPELRI® (revefenacin) Development And Commercialization Agreement To Include China And Adjacent Territories

Theravance Biopharma And Mylan Expand YUPELRI® (revefenacin) Development And Commercialization Agreement To Include China And Adjacent Territories

First and only once-daily, nebulized bronchodilator has potential to address unmet needs of China's nearly 100 million chronic obstructive pulmonary disease (COPD) patients

Theravance Biopharma And Mylan Expand YUPELRI® (revefenacin) Development And Commercialization Agreement To Include China And Adjacent Territories

Theravance Biopharma And Mylan Expand YUPELRI® (revefenacin) Development And Commercialization Agreement To Include China And Adjacent Territories

First and only once-daily, nebulized bronchodilator has potential to address unmet needs of China's nearly 100 million chronic obstructive pulmonary disease (COPD) patients

Theravance Biopharma And Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis At The 2019 ATS International Conference

Theravance Biopharma And Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis At The 2019 ATS International Conference

Post-Hoc Analysis Highlights the Potential Role of YUPELRI in the COPD Treatment Paradigm

Theravance Biopharma And Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis At The 2019 ATS International Conference

Theravance Biopharma And Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis At The 2019 ATS International Conference

Post-Hoc Analysis Highlights the Potential Role of YUPELRI in the COPD Treatment Paradigm

Mylan To Host Investor Day On July 31, 2019 In New York City

Mylan To Host Investor Day On July 31, 2019 In New York City

HERTFORDSHIRE, England and PITTSBURGH, May 17, 2019 /PRNewswire/ --  Mylan N.V.

Mylan And Biocon To Present Final Overall Survival Data For Ogivri™ (trastuzumab-dkst), A Biosimilar To Herceptin®, At The American Society Of Clinical Oncology (ASCO) Annual Meeting

Mylan And Biocon To Present Final Overall Survival Data For Ogivri™ (trastuzumab-dkst), A Biosimilar To Herceptin®, At The American Society Of Clinical Oncology (ASCO) Annual Meeting

Ogivri™ is the first biosimilar for Herceptin® approved by the U.S. Food and Drug Administration (FDA) for all indications including HER2-positive breast and gastric cancers

Teva Falls as Drugmakers Alleged to Have Artificially Inflated Prices

Teva Falls as Drugmakers Alleged to Have Artificially Inflated Prices

Attorneys general from 44 states allege the nation's largest generic drugmakers conspired to artificially inflate and manipulate prices for more than 100 different generic drugs.

Stock Selloff, Trade War, Teva, Take-Two and Oil Prices - 5 Things You Must Know

Stock Selloff, Trade War, Teva, Take-Two and Oil Prices - 5 Things You Must Know

U.S. stock futures fall sharply after China vows to stand its ground in the escalating trade war with the United States; oil prices surge after Saudi Arabia alleges two of its tankers were victims of a 'sabotage attack,' Teva and other drugmakers are alleged to have conspired to artificially inflate and manipulate prices for generic drugs.

TheStreet Quant Rating: D+ (Sell)